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A MURINE model for acute lethal graft vs. host disease
(GVHD) was used to study the role that a number of
cytokines play in the development of lethal GVHD. In this
study we focused on the role of IL-1, IL-2, IL-4, IL-6,
IFN- and TNF-. Lethally irradiated (C57BL CBA)F1
mice were reconstituted either with 107 allogeneic BALB/c
spleen cells or with a similar number of syngeneic cells,
as a control. A significant rise in serum levels of IL-6,
TNF-g and IFN- levels was found in allogeneically
reconstituted mice. This is in contrast to the syngeneic
control group in which no rise was seen. Serum IL-2 and
IL-4 levels were below the detection limit. In the super-
natant ofCon A stimulated spleen cells from allogeneically
reconstituted mice IL-6, IFN- and TNF- concentrations
were increased. The expression ofmRNA for cytokines as
detected by reverse transcription PCR was studied in
spleen cells. In the allogeneic reconstituted mice the
mRNA expression of IL-lg, IL-2, IL-6, IFN- and TNF-g
displayed faster kinetics compared with that in syngeneic
reconstituted mice. The effect of treatment with recombi-
nant cytokines, antibodies to cytokines and to cytokine
receptors on the development ofGVHD was investigated.
Administration of recombinant IL-2 to allogeneically re-
constituted mice strongly increased the morbidity and
mortality whereas injection of IL-lg and TNF-cz did not
influence survival. Administration of antibodies against
IL-2 or the IL-2 receptor decreased the morbidity and
mortality. Anti-IL-6, anti-IFN-, and anti-TNF-cz mAB, on
the other hand, did not affect the morbidity and mortality
of GVHD. The results of this study suggest successive
waves of cytokine-secreting cell populations consistent
with the induction of an inflammatory response in the
development of acute GVH disease.
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Introduction
Graft vs. host disease (GVHD) is the result of
activation of transplanted donor T cells by
alloantigens on host tissues. The recognition of
these antigens by T lymphocytes initiates a cascade
of events which leads to the production of cytokines
and the expression of their receptors. One of the
first cytokines produced by activated T cells is IL-2.
This cytokine enhances the expression of the IL-2
receptor and induces proliferation and activation of
T cells.
2 Activated T lymphocytes differentiate into
cells that produce a variety of cytokines.
3 This
production of cytokines leads to recruitment and
activation of other cell types such as B lymphocytes,
macrophages and natural killer cells. 1’2 These cell
types are involved in the process that leads to
clinically overt GVHD and tissue destruction.
Recently, it was suggested that in murine models
of acute and chronic GVHD, the development of
acute and chronic GVHD associated pathological
changes is related to differential cytokine produc-
tion by activated T cells.
3 The subset of T cells
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activated and their cascades of sequential activation
might be reflected in the set of cytokines that can
be demonstrated during GVHD. For example,
while T cell cytokines such as IL-4 and IL-10 play
important roles in chronic GVHD, no clear role of
these cytokines in acute models has been
demonstrated yet.
The number of cytokines such as IL-1, IL-2,
IFN-y, TNF-0 that are reported to play a role in
experimental as well as clinical GVHD steadily
increases.
4-8 The data from the literature, however,
are not unequivocal. Moreover, many studies deal
with only one particular cytokine. To improve
current diagnostic and therapeutic approaches
insight into the sequential involvement of the cells
that play a role in GVHD, the cytokines they
produce, their interactions and their regulation, is
necessary.
The authors’ previous investigations into the
cellular aspects of murine GVHD is followed by
this study of the role of cytokines, using a model
of acute GVHD in lethally irradiated recipients in
which CD4+ T cells play a predominant role.9’1
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For this study, serum samples and supernatants of
spleen cell cultures were analysed for the presence
of various cytokines, and spleen cell suspensions for
the expression ofmRNA for cytokines. The role of
these cytokines in morbidity and mortality of
GVHD was further assessed by treating allogeneic-
ally reconstituted mice with recombinant cytokines
and monoclonal antibodies to cytokines and
cytokine receptors.
Materials and Methods
Mice: (C57BL/Ka x CBA/Rij)F1 (H-2b/q) and
BALB/c (H-2d) mice were bred at the Department
of Immunology of the Erasmus University. Recipi-
ent mice were age matched and 12-18 weeks old
when entered in the experiments. During the
experiments, mice were kept two per cage in
light-cycled rooms and had access to acidified water
and pelleted food ad libitum.
Induction of GVHD: GVH reactions were induced in
lethally irradiated (10 Gy) mice by i.v. injection of
107 allogeneic spleen cells within 24h after
irradiation. Irradiation was performed in a
caesium-137 source (Gammacell 40, Atomic Energy
of Canada, Ottawa, Canada) with a dose rate of
1.15 Gy/min. Mice were examined daily for the
development of signs ofGVHD, such as ruffled fur,
hunched posture, decreased physical activity,
wasting, skin lesions and diarrhoea, and for
mortality. The body weight was determined two or
three times per week during the first 4 weeks after
GVHD induction. Thereafter the frequency was
decreased depending on the health status of the
mice. Mice judged moribund were killed. Irradiated
control mice reconstituted with syngeneic cells
survived >250 days without signs of disease.
Radiation controls died between days 10 and 22.
Collection ofserum and tissue culture: Mice were sacrificed
using carbon dioxide. Blood collected by cardiac
puncture was allowed to clot overnight at 4C and
centrifuged for 5 min in an Eppendorf centrifuge
(International Equipment Company, Needham,
MA). Serum samples were divided into aliquots and
stored at -70C. Spleen cell suspensions were
prepared in BSS. Nucleated cell concentrations
were determined with a Coulter Counter model
ZB1. Viability of the cell suspensions as determined
by the trypan blue exclusion method was > 90%.
For the determination of cytokines in spleen cell
supernatants, spleen cells were cultured in RPMI
1640 tissue culture medium, supplemented with
10% FCS, glutamine and antibiotics according to
Cleveland et al.1 A concentration of 5 x 105
cells/well was seeded in five-fold in 96-well
flat-bottom microtitre plates (Falcon, Becton
Dickinson, Lincoln Park, NJ) and cultured for 24 h
at 37C and 5% CO2 in the presence of Con A
(1/ig/ml). The samples were centrifuged and the
supernatants were collected and stored in aliquots
at -70C. For each cytokine all samples were
assayed simultaneously.
Determination of cytokines: IL-2, IL-6 and TNF-0 were
determined in a bioassay using CTLL-2, B9 and
WEHI164 (clone 13) indicator cells respectively, as
described previously.
12-14 The MTT assay was used
to quantitate the proliferative and cytotoxic
activity.
15 The procedure was described previously
with minor modifications.
16 Briefly, 30 #1 MTT
solution (5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (Sigma, St Louis,
MO, in PBS) was added to each well. Plates were
incubated for 3.5 h at 37C with 5% CO2. The
supernatant was discarded and 100 #1 DMSO
(Merck, Darmstadt, Germany) was added to each
well. The plates were monitored on a Titertek
Multiskan MCC 96-well ELISA plate reader (Flow
Laboratories, Ayrshire, Scotland) at a wavelength
of 510 nm. The experimental values were corrected
for background values. IFN-2 was determined in
ELISA as described. 17
Detection of mRNA for cytokines: RNA was isolated
from spleen cell preparations using guanidinium
thiocyanate extraction in combination with gradient
centrifugation on 5.7 M caesium chloride for 18 h
in an ultracentrifuge (Sorvall, Du Pont, Newtown,
CT) as described, is After ethanol precipitation 1 #g
RNA was used in a reverse transcriptase reaction.
For amplification 35 cycles (1 min at 94C for
denaturation, 2 min at 55C for annealing and 3 min
at 72C for primer extension) were performed,
using a DNA thermal cycler (Perkin-Elmer,
Gouda, The Netherlands). For all samples sense and
anti-sense primer sets specific for IL-la, IL-2, IL-6,
IFN-2, TNF-0 were used as described.
18 A primer
set specific for the housekeeping gene hypox-
anthine phosphatidyl ribosyltransferase (HPRT)
was used as an internal control.
Recombinant cytokines: Recombinant cytokines were
administered in vivo by s.c. injection in the inguinal
region, in a volume of 0.25-0.5 ml. Recombinant
(r) IL-2 was kindly provided by Dr G. Malainer
(Sandoz Forschungsinstitut, Wien, Austria). IL-2
was shown to enhance murine CTLL-2 prolifera-
tion based bio-assay and its activity could be
neutralized effectively by addition of anti-IL-2
antibodies ($4B6.1).9 Human IL-10 was a gift from
Hoffman-La Roche, Mijdrecht, The Netherlands.
Recombinant murine (rm) IFN-y was a kind gift of
Dr R. L. Coffman (DNAX Research Institute, Palo
Alto, CA). The rmlL-6 was purchased from British
Biotechnology, Abingdon, UK. Human rTNF-0
was a gift from BASF/Knoll, Ludwigshafen,
Germany.
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LPS and antibodies: LPS-B (Salmonella typhosa 0901)
was purchased from Difco Laboratories, Detroit,
MI. Mice received a dose of 100 #g i.p. dissolved
in BSS.2
For in vivo treatment, anti-IL-2 (S4B6.1),
19
anti-IL-6 (MP 20F3),
21 anti-IFN-2 (XMG 1.2)
17 and
anti-TNF-cz (XT22),
21 producing hybridomas were
used to purify antibodies from. An anti-IL-2R
(PC61) producing hybridoma was obtained from
the American Type Culture Collection. The mAb
were purified from ascites by protein G (Pierce
Europe, Oud-Beijerland, The Netherlands) affinity
chromatography and subsequently administered by
i.p. injection in doses up to 1 mg. Rat IgG1 in the
serum of anti-cytokine antibody treated mice was
determined by a specific ELISA.
22
Statistical analysis: Differences between groups were
analysed using the Student’s t-test or the
Wilcoxon-Mann-Whitney statistic. Values of p <
0.05 were considered significant.
Results
Serum cytokine levels" Groups of (C57BL x CBA)F1
mice were lethally irradiated and reconstituted with
either 107 allogeneic BALB/c or 107 syngeneic
spleen cells as controls. Signs of disease were
detectable in the allogeneically reconstituted mice
from day 6 onwards, whereas mortality occurred
from day 8 onwards. The mean survival time of
these mice was 12.5 _--b 4.9 days. The syngeneically
reconstituted mice survived > 250 days without any
symptom of disease.
To demonstrate that T cells were involved in the
production of IFN-2, mice (n 5) were treated
with a single i.p. dose of 100/g anti-Thy-1 at 24 h
after reconstitution with allogeneic or syngeneic
spleen cells.9 Serum IFN-, levels at day 7 were
22 _+ 5 #g/ml in the allogeneic group. The serum
IFN-2 levels in anti-Thy-1 treated allogeneically
reconstituted mice were 6 -+- 3 #g/ml and compar-
able with those of the syngeneic group (4 _+ 2
#g/ml).l These data show that the observed serum
IFN-y was produced by T cells.
In order to examine the cytokine production, five
mice from both groups were sacrificed at 1, 2, 3, 4,
5, 6, 7, 8 and 10 days after reconstitution. Serum
samples from these mice were analysed for the
presence of IL-2, IL-4, IL-6, IFN-y and TNF-0.
Figure 1A illustrates the IL-6 levels in serum, which
increased at day 4 after allogeneic reconstitution.
From day 5 onward these IL-6 levels were
significantly increased (p < 0.05) compared with the
syngeneically reconstituted mice in which no rise in
IL-6 levels was seen. Serum IFN-, levels in the
allogeneically reconstituted mice increased at day 4
with a peak on day 5 and 6 (Fig. 1B). On the peak
days these levels were significantly higher (p <
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FIG. 1. Serum IL-6, IFN-? and TNF- levels in acute GVHD. Lethally
irradiated (C57BL x CBA)F1 mice were reconstituted either with 107
allogeneic BALB/c spleen cells or 107 syngeneic spleen cells. From each
of these two groups the serum levels of IL-6 (A) and IFN-? (B) was
examined from day until day 10 after reconstitution. TNF- serum levels
(C) were determined on days 3, 5 and 7. Each point represents the
arithmetic mean __. S.E.M. (n 5).
0.05) compared with the syngeneically reconstituted
group in which no rise of IFN-, was seen. In the
allogeneic group, TNF- levels were significantly
higher on day 7 only when compared with the
syngeneic control (Fig. lC). IL-2 and IL-4 levels
were below the detection limit: <0.1 U/ml (data
not shown).
Cytokines in spleen cell supernatants Since cytokine levels
in the serum are considered an indirect reflection of
the cytokine production in the spleen, we were
interested in the cytokine production by the spleen
cells themselves at various times after induction of
GVHD. Therefore, lethally irradiated (C57BL x
CBA)F1 mice were reconstituted with either 107
BALB/c or syngeneic spleen cells. On days 3, 5 and
7 after reconstitution spleen cells from three mice
of each group were cultured in the presence of Con
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A. After 24 h culture, levels of IL-2, IL-4, IL-6,
IFN-y and TNF-0 were determined in the
supernatants (n 3). Figure 2 (A-C) shows that
IL-6, IFN-y and TNF- levels in the allogeneically
reconstituted group were significantly increased
(p < 0.05) compared with syngeneically recon-
stituted mice. While the production of IFN-2 and
TNF- were peaking at day 5 after induction of
GVHD, IL-6 production decayed from an initial
high production at day 3. Preliminary data
substantiate these increased productions by finding
increased frequencies of IL-6, IFN-y and TNF-0
secreting cells using newly developed ELISA
plaque assays (data not shown).
Detection of cytokine mRNA: From both groups of
mice spleen cell suspensions were analysed for the
presence of cytokine mRNA on days 1, 2, 4, 5 and
7 after reconstitution indicating the actual produc-
tion of these cytokines in vivo. Figure 3 shows a
1.500
000
750
250
o;
(A)
allogeneic
syngeneic
Days after reconstitution
so (B)
40 allogeneic
syngeneic
10
Days after reonstitution
100
(c)
75 allogeneJc /
E
, so
25
Days after reconstitution
FIG. 2. IL-6 (A), IFN-7 (B) and TNF- (C) levels in the supernatant of
24h sleen cell cultures. From alloenicallg and sgneneicallg
reconstituted mice sleen clls were cultured for 24 h in the resence of
Con N. ach oint mresents the arithmetic mean of the ctokine
level S..M. (n a).
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FIG. 3. Expression of IL-1 mRNA in lethally irradiated (C57BL x CBA)F1
mice reconstituted with either 10 allogeneic BALB/c spleen cells or
syngeneic F1 spleen cells. Total splenic RNA was extracted on days 1,
2, 4, 5 and 7, cDNA was prepared and reverse type PCR analysis was
performed using an HPRT primer set (lanes 1-6) or an IL-I primer set
(lanes 7-1 2). Lane M: base pair marker (4 74 RF DNA Hae III digest),
lanes and 7, 3 and 9, 5 and 11 represent syngeneically reconstituted
mice analysed on days 4, 5 and 7, respectively. Lanes 2 and 8, 4 and 10,
6 and 2 represent allogeneically reconstituted mice analysed on days 4,
5 and 7, respectively.
typical result of the RT-PCR analysis of IL-1
mRNA expression in both syngeneically and
allogeneically reconstituted mice. Allogeneically
reconstituted mice displayed an early and abundant
expression of IL-I starting from day 1 after
reconstitution. Expression of IL-1 mRNA could
also be detected in syngeneically reconstituted
animals only by day 7. The results of this analysis
are summarized in Table 1. As shown in Table 1,
in the allogeneically reconstituted mice mRNA
levels of IL-1, IL-6 and TNF- were detectable
from day 1, while mRNA levels of IL-2 and IFN-2
were detectable at days 4 and 5, respectively, by
using this RT-PCR analysis. Until day 7 these
cytokines were not detectable in the syngeneically
reconstituted group. On day 7 the mRNA levels
were similar in both groups.
Eect of administration of recombinant cytokines: Based
upon the expression in the early development of
GVHD of IL-1, IL-2 and TNF- these cytokines
were chosen to modulate the developing signs of
GVHD. We investigated the effect of administra,
tion of rIL-2 to (C57BL x CBA)F1 mice that were
lethally irradiated and reconstituted with 107
BALB/c spleen cells. The morbidity in both groups
was comparable. IL-2 was injected twice daily at a
dose of 50000IU, either from days 0 to 3 or
alternatively, from days 6 to 9 after reconstitution
based on the studies of Sykes et al. 23 The results are
shown in Fig. 4A. IL-2 administration from days 6
to 9 resulted in increased mortality compared with
the non-treated control group. However, since the
GVHD in this experiment was more chronic than
in other experiments using the same strain
combinations this is not considered a relevant effect.
IL-2 injection from days 6 to 9 on the other hand
resulted in a significantly increased mortality.
Treatment with a lower dose of 5 000 IU twice daily
did not influence the morbidity or mortality in this
model of GVHD (data not shown).
The effect of rhIL-1 was studied after a single
dose of 400ng of IL-I on day -1, 3 or 6. It
appeared that IL-1o treatment did not influence
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Table 1. mRNA expression for IL-I, IL-2, IL-6, IFN- and TNF- during GVHD
Days after reconstitution
2 4 5 7
Cytokine allo syn allo syn allo syn allo syn allo syn
IL-I + + + + _+ _+
IL-2 + + + +
IL-6 _+ _+ + + _+
IFN- + _+ +_
TNF- ___
+ + + +
(C57BL x CBA)F1 mice were lethally irradiated reconstituted with 107 allogeneic (allo) BALB/c or syngeneic
(syn) spleen cells. At days 1,2, 4, 5 and 7 after reconstitution, pooled spleen cells of both groups were analysed
for the expression of mRNA for IL-I, IL-2, IL-6, IFN-2 and TNF- (n 5).
+ strongly visible signal, ___
weakly visible signal, no visible pcr product.
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FIG. 4. (A) Effect of administration of rlL-2 in vivo on GVHD. Lethally
irradiated (C57BL x CBA)F1 mice were reconstituted with 0 BALB/c
spleen cells and subsequently treated twice daily with 50000 IU rlL-2
s.c. at days 0 to 3 or 6 to 9 after reconstitution (n 8). (B) Effect of
rlL-l. GVHD was induced as indicated. A dose of 400 ng of rlL-1 was
given either on days -1, 3 or 6 after reconstitution (n 8). (C) Effect
of rTNF-. GVHD was induced as indicated. A dose of 2/g of rTNF-
was given on either day -1, 3 or 6 after reconstitution (n 8).
the survival (Fig. 4B). The effect of a single dose of
2/g of rhTNF- was studied after injection on
either day -1, 3 or 6. TNF- administration had
no effect on the survival (Fig. 3).
Effect of injection of LPS: In vivo injection of LPS is
known to induce IL-1, IL-6 and TNF- production
in a time dependent fashion. LPS might therefore
modulate the course of GVHD.
6 We studied
whether injection of LPS at various days after
reconstitution influenced the mortality of GVHD
in the BALB/c-(C57BL x CBA)F1 strain combina-
tion in three independent experiments. In a
representative experiment, groups of mice received
100/g LPS either on day -1, 0, 1, 3 or 6 after
allogeneic reconstitution. It appeared that the effect
of LPS administration was dependent on the time
of injection (Fig. 5). LPS did not enhance GVHD
and mortality when injected on day 1, 3 or 6 after
reconstitution. The effect appeared stronger when
the LPS was administered at a later time point after
reconstitution. In contrast, injection of LPS on day
-1 appeared to inhibit GVHD. In all experiments,
a rather acute GVHD was induced in the
non-treated allogeneically reconstituted mice.
Effect of anti-cytokine and anti-cytokine receptor ,nAB"
(C57BL x CBA)F1 mice were lethally irradiated,
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FIG. 5. Effect of LPS on the development of acute GVHD. Groups of
lethally irradiated (C57BLx CBA)F1 mice reconstituted with 10
BALB/c spleen cells were i.p. injected with 100/g of LPS on either day
-1, 0, 1, 3 or 6 after reconstitution (n 0).
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FIG. 6. Effect of anti-lL-2 and anti-lL-2R mAb treatment. Lethally
irradiated (C57BL CBA) F1 mice reconstituted with 107 BALB/c spleen
cells were injected with 0.1 ml anti-lL-2 ascitic fluid or mg anti-lL-2R
mAb day after reconstitution (n 10).
reconstituted with 107 BALB/c spleen cells and
injected the day after reconstitution with rat
antibodies against several cytokines in doses up to
1 mg that have been widely shown to be sufficient
to neutralize the respective cytokine activities in a
variety of systems. Upon treatment with these mAb
detectable levels (> 1 #g/ml) of rat IgG occurred
for a period up to 14 days (data not shown).
Combinations of several anti-cytokine antibodies
specific for TNF-, IFN-2 and IL-6 did not result
in a significant increase of the survival. Anti-IL-2
and anti-IL-2R mAb, however, did affect the
development of GVHD. These mAb were injected
the day after reconstitution. As shown in Fig. 6,
both mAb were able to enhance the survival
significantly (p < 0.05). However, mortality did
occur, starting on day 38. This indicates that the
inhibitory effect of anti-IL-2 and anti-IL-2R mAb
was only temporary at the dose tested.
Discussion
The main finding in this study is that in
developing acute GVHD the production of IL-6,
IFN- and TNF- is significantly increased
although IL-2 is the crucial cytokine which acts as
a target for intervention studies. Most studies on
the role of cytokines in GVHD deal with only one
particular cytokine. We studied the role of several
cytokines that are potentially involved in GVHD,
by cytokine mRNA expression, analysis of
cytokines in serum and culture supernatant and by
in vivo administration of recombinant cytokines or
anti-cytokine and anti-cytokine receptor mAb.
These data substantiate the important role that
cytokines play in GVHD.24 In GVHD, a role for
IL-1, IL-2, IFN-2 and TNF- (’cytokine storm’)
has been postulated.
4-8 Since IL-1 is produced in
increasing amounts as clinical GVHD progresses,
blocking of 1L-1 activity led to strongly enhanced
survival from GVHD in mice.8’2s Blocking of IL-1
might interfere with early T-cell activation.
2 In the
murine model used, we have earlier demonstrated
that CD4+ T cells play a dominant role in the
induction ofGVHD.
9 Here we show by anti-Thy-1
treatment that the production of some cytokines
(IFN-y) is dependent on T cells. In this study
treatment with IL-1 did not result in enhanced
symptoms of GVHD, which might be caused by
the dose used. On the other hand, conflicting data
exist in which treatment with 10/lg IL-1 resulted
in enhanced survival in lethally irradiated and
allogeneically reconstituted mice.
26 With the devel-
opment of cytokine ELISA plaque assays increased
frequencies of cytokine-secreting cells were ob-
served in con A stimulated spleen cell cultures.
These data together with the observed low, but
relatively constant cytokine production rate per
cell,
iv argue for a higher proportion of IL-6, IFN-
and TNF-0 secreting cells in the spleens of mice
suffering from GVHD.
A. surprising result was the sequential cytokine
mRNA expression specific for the allogeneically
reconstituted mice by RT-PCR analysis. The
differential kinetics of the cytokine expression
resulted in early expression of IL-10q IL-6 and
TNF-0 (day 1) while IL-2 and IFN-2 were found
only later (days 4 and 5). In the syngeneic group
cytokine gene expression was not detected before
day 7. The kinetics of the cytokine mRNA
expression is reflected in the production found in
Con A supernatants for IL-6, TNF- and IFN-y.
The detection of these cytokines in the serum is
delayed by several days. The peak of IFN-2 activity
coincided with a strong increase in the number of
CD4+ T cells in the spleen
1 and also with DTH
reactivity.
28 This might reflect Thl activity, as an
important event in the development ofGVHD. The
peak of IL-6 activity coincided with a strong
increase in the number of CD8+ T cells.1 These
observations might reflect the sequential involve-
ment of several cell populations like activated
monocytes/macrophages, CD4+ T cells and pos-
sibly CD8+ T cells and their cytokines ’in our
model.
24 While the findings in this study suggest an
important role for monokines in mediating acute
GVHD, it must be remembered that GVHD is
initiated by T cells.3’1 Ford et al. have shown in a
sponge matrix allograft model that the occurrence
of IL-6 coincided with cytotoxic T cell develop-
ment.
29 A number of studies suggests that also
TNF- plays an important role in the pathogenesis
of GVHD.7’3’31 elevated serum levels of TNF-
preceded clinical symptoms of GVHD. A possible
explanation for the difference between the cytokine
gene expression and production in the syngeneic
and allogeneic group could be a higher frequency
of cytokine-producing cells in the allogeneic group.
This possibility is currently under investigation. So
far, few studies have been described aiming at
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modulating GVHD by treatment with recombinant
cytokines rather than anti-cytokine antibodies or
receptor agonists in ///’//0,26,32
The impact of the balance between Thl and Th2
cells for the induction and pathogenesis of GVHD
is still unclear. Several groups found evidence for
predominance of a Th2 response in a model for
chronic GVHD. 33’34 In our model IL-2 and IL-4
were not detectable in the serum, possibly as a result
of rapid consumption. However, the involvement
of IL-2 is implicated by: (a) the finding of enhanced
IL-2 mRNA expression after allogeneic reconstitu-
tion; (b) the observation that exogenous IL-2
enhanced the mortality; and (c) the observation that
anti-IL-2 and anti-IL-iR mAb were able to decrease
the morbidity and mortality of GVHD. Enhanced
mortality ofGVHD by exogenous 1L-2 administra-
tion was also reported by others. 1’23’32 The fact that
IL-2 administration at a later stage (days 6 to 9)
enhanced the mortality more strongly than IL-2
administered during the first few days after
reconstitution, suggests that the strongest effect of
exogenous 1L-2 is exerted on CD8+ T cells.
However, CD4+ T cells are activated and give rise
to large amounts of IL-2 only in the early phase of
GVHD (starting from day 4). They might be less
dependent on exogenous IL-2, since they can
produce IL-2 themselves. This IL-2 leads to
expansion of CD8+ T cells, which is the dominant
cell population in the development of GVHD.
Sykes et al. found that IL-2 treatment given early
after allogeneic reconstitution even delayed the
development of GVHD. This effect was most
clearly found in chronic GVHD and was dependent
on the dose of IL-2. Recently, these authors were
able to demonstrate that early IL-2 administration
had an inhibitory effect on donor T cells.32
Apparently, in our model of acute GVHD such a
beneficial effect of early IL-2 administration did not
occur. The concept that activation of Thl and Th2
subsets led to differential cytokine production and
subsequently disease associated pathology may also
underline the varied manifestations ofGVHD. The
balance between Thl cells (mediating inflammatory
and cytotoxic T cell responses) and Th2 cells
(involved in humoral immunity) will thus de-
termine the acuteness or chronicity of the
pathological changes in induced GVHD.
The administrati6n of LPS, which is known to
induce the sequential production of a number of
cytokines, such as IL-1, IL-6 and TNF-0,s also
influenced the morbidity and mortality of GVHD.
Since LPS injection enhanced the development of
GVHD and mortality the results substantiate the
relevance of these cytokines detected in the serum
of allogeneically reconstituted mice. This finding is
consistent with the hypothesis of an inflammatory
cytokine production as the common pathway of
acute GVHD.
36 During GVHD macrophages
become primed as the result of the allogeneic
reaction and subsequent production of TNF- and
possibly IL-1 is triggered.
2s The earlier after
reconstitution that the LPS was administered, the
less the mortality was enhanced. Administration of
LPS one day before allogeneic reconstitution even
delayed the development of GVHD. We also
studied the effect of exogenous IL-1 and TNF-0
administration. However, it appeared that at the
dose tested, neither IL-1 nor TNF- influenced the
survival. It is tempting to speculate that this is due
to the presence of IL-1 receptor antagonist and
soluble TNF-0 receptors in the serum. These
results, however, could be compromised by the
rather acute GVHD in the control mice thereby
obscuring some possible activities mediated by
LPS. On the other hand, the dose of LPS used was
sufficiently high to expect strong in vivo effects,i
More insight into the involvement of cytokines
in GVHD can also be obtained by studying the
effect of neutralizing mAb directed to cytokines or
their receptors. We studied the effect of anti-IL-6,
anti-IFN-y and anti-TNF-0 mAb. Even repeated or
combined administration of these mAb in doses that
are known to exert distinct in vivo effects21’32’35’37 did
not influence the morbidity or mortality ofGVHD
in our model. Thus far, most reports dealing with
administration of a single mAb to a particular
cytokine show that a beneficial effect depends on
co-administration of immunosuppressive agents,
such as cyclosporine A. 38 Also, in human bone
marrow transplantation treatment with a mono-
clonal anti-TNF-0 antibody in combination with
cyclosporin was found to be ineffective in
preventing GVHD in the majority of cases.
39 It has
also been described that specific lesions, e.g. gut
lesions, due to GVHD can improve upon
anti-cytokine (anti-IFN-2) treatment only, but
decreased mortality has not been found.4’33 It can
be speculated that once a GVH reaction has been
initiated, a variety of cytokines is released (’ cytokine
storm’) which have overlapping activities based on
the degeneracy in the cytokine network. Blocking
of the activity of only one particular cytokine will
be ineffective in that case. Another possibility is that
the local amount of cytokines produced in GVHD
is so high that even higher systemic doses are
required. Finally, it cannot be excluded that in
GVHD cytokines other than those studied here, are
involved. Recently, IL-7 was reported to be
involved in tumour rejection
4 whereas IL-8 levels
were found to be elevated after liver transplanta-
tion.41
The observation that anti-IL-2 mAb so far is the
only anti-cytokine mAb that is able to enhance the
survival might be explained by the critical role of
IL-2 in T cell activation.2 Similarly, anti-IL-iR mAb
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were able to reduce the morbidity and mortality of
GVHD. It is likely that blockade of the cytokine
cascade is most easy during the induction phase.
These data point to a critical role for IL-2 as a
possible therapeutic target in the prevention of
GVH. Preliminary data in humans show also a
beneficial effect of anti-IL-2R treatment in
GVHD.42 The results of serum and culture
supernatant analyses suggest that, besides IL-2,
IL-6, 1FN-y and TNF- are involved as well. The
observation that serum IL-6, IFN-2 and TNF-
levels are elevated, before symptoms of GVHD
become apparent, suggests that careful evaluation
of cytokines in serum might be useful for the early
detection ofGVHD. It has to be stressed, however,
that elevation of cytokine levels is not restricted to
alloreactivity but occurs also during bacterial and
viral infections and that determination of cytokines
at present can be used only to support current
diagnostic procedures.
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